Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
IMU
vs
S
S&P/ASX 300
IMU
Over the past 12 months, IMU has underperformed S&P/ASX 300, delivering a return of -88% compared to S&P/ASX 300's +5% growth.
Stocks Performance
IMU vs S&P/ASX 300
Performance Gap
IMU vs S&P/ASX 300
Create a free account · No card needed
Performance By Year
IMU vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Imugene Ltd
Glance View
Imugene Ltd is a biotechnology company that develops cancer immunotherapy drugs. Its main work is to design and test treatments that help the body’s immune system recognize and attack cancer cells. The company does not sell a broad portfolio of medicines; instead, it focuses on a pipeline of experimental therapies that are still in development and clinical testing. Imugene’s customers are not patients directly. Its money comes mainly from capital raised to fund research, along with partnerships or licensing deals if its drug programs attract larger pharmaceutical companies. The business is built around creating drug candidates, running trials, and advancing the most promising ones toward approval, which is a long, high-risk process typical of biotech. What makes Imugene different is its role in the drug development chain: it is an early-stage developer of novel cancer treatments rather than a drug maker with established products. Its value depends on whether its scientific programs can show enough safety and effectiveness to move forward, which is why investors follow its clinical progress closely.
Create a free account · No card needed
